Dry Eye

Oculis announces positive Phase 2b results for dry eye disease treatment

Oculis Holding AG has reported positive topline results from its Phase 2b RELIEF trial evaluating licaminlimab, an anti-TNFα eye drop, for dry eye disease, according to a company press release. The study demonstrated significant improvements in multiple efficacy endpoints, particularly in patients with a TNFR1 genetic biomarker. Licaminlimab showed a...